Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
Chad MoretzBeth HahnJohn WhiteAlyssa Goolsby HunterBreanna EssoiCaitlin ElliottRiju RayPublished in: International journal of chronic obstructive pulmonary disease (2020)
After controlling for baseline characteristics, symptom burden was similar between patients receiving UMEC/VI or FP/SAL. GOLD classification using mMRC produced more conservative results compared with CAT, potentially underestimating patient symptoms. Many patients receiving FP/SAL were classified as GOLD A or B, despite GOLD recommending non-ICS-containing therapy in these patients. These findings support the need for routine assessment of symptoms in patients with COPD.
Keyphrases
- chronic obstructive pulmonary disease
- machine learning
- end stage renal disease
- deep learning
- silver nanoparticles
- newly diagnosed
- lung function
- patient reported
- chronic kidney disease
- prognostic factors
- stem cells
- risk factors
- healthcare
- case report
- peritoneal dialysis
- sleep quality
- patient reported outcomes
- mesenchymal stem cells
- physical activity
- smoking cessation
- replacement therapy